anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The multicomponent exercise program consisted of strength and balance exercises performed on two non-consecutive days per week and lasting approximately an hour per session. Strength exercises were mainly focused on lower limb strengthening. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. As for balance exercises, the first weeks consisted of mainly less complex static balance exercises and progressed to more complex and dynamic balance exercises. These exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention.
The invention relates to a preparation method of a capsaicin-vitamin E prodrug self-assembly nano drug delivery system. Capsaicin-vitamin E prodrugs (Cap-SVE) are prepared by linking capsaicin to vitamin E using dithiodiglycolic acid. On the basis, capsaicin-vitamin E prodrug self-assembly nanoparticles (Cap-SVE NPs) are further prepared. The prodrug self-assembled nanoparticles have some characteristics: the average particle diameter is less than 200nm, the particles are uniformly distributed in a similar spherical shape, and the drug loading can reach 8 mg/mL calculated by capsaicin ‑1 . Is stable under acidic condition and is hydrolyzed gradually under the condition of pH 7.4. The prodrug self-assembly nanoparticles can reduce gastrointestinal irritation of capsaicin, remarkably improve bioavailability of the capsaicin, increase targeting effect of the capsaicin in liver, and remarkably improve the anti-oxidation and blood fat reduction drug effects of the capsaicin. Good stability, high safety and wide market prospect.
PURPOSE:To advantageously obtain a dimeric immunoglobulin (dIgA) in a large amount, by cultivating a specific hybridoma, reductively decomposing the resultant complex type human immunoglobulin and alkylating the decomposition product. CONSTITUTION:A parent strain, e.g. human B lymphoblastic cell 6-thioguanine- resistant HO-323 strain, capable of synthesizing mu-chains and human normal lymphocytes, e.g. lymphocytes derived from lymphonodus extracted from patients with pulmonary cancer, are subjected to cell fusion and give a hybridoma, which is then cloned to separate a hybridoma strain capable of simultaneously producing IgA and IgM. The resultant strain is further cultivated to produce complex type human immunoglobulin, which is then subjected to reductive decomposition with a reducing agent, e.g. cysteine, under mild condition in a nitrogen gas stream and then alkylated with monoiodoacetic acid, etc. The resultant decomposed immunoglobulin is treated by gel filtration or chromatography to separate dimeric immunoglobulin (dIgA) fraction and collect the aimed dIgA.
BACKGROUND: It remains unclear whether physiologic differences exist in musculoskeletal ultrasound nerve measurements when comparing bilateral and unilateral carpal tunnel syndrome (CTS) patients. Similarly, the influence of body mass index on CTS severity is not well characterized.
METHODS: Unilateral and bilateral CTS patients were seen from October of 2014 to February of 2021. Obese and nonobese CTS patients were compared. Median nerve cross-sectional area (CSA), Boston Carpal Tunnel Syndrome Questionnaire (BCTSQ), and six-item Carpal Tunnel Symptom Score (CTS-6) measures were obtained. Nerve conduction studies recorded distal motor latency (DML) and distal sensory latency (DSL). Statistical analysis used Wilcoxon signed rank testing for paired continuous variables, Mann-Whitney U testing for nonpaired continuous variables, and chi-square testing for continuous variables, with a significance level of P < 0.05.
RESULTS: A total of 109 (218 nerves) bilateral and 112 (112 nerves) unilateral CTS patients were reviewed. Bilateral patients had larger median nerve CSAs on their more symptomatic side, when defined by BCTSQ score ( P < 0.0001), CTS-6 score ( P < 0.0001), DML ( P < 0.0001), and DSL ( P < 0.01). Bilateral patients also had higher symptom severity scale ( P < 0.01) and DSL ( P < 0.001) outcomes compared with unilateral patients. Obese patients had higher median nerve CSA ( P < 0.01), prolonged DML, and prolonged DSL ( P < 0.0001) values despite similar CTS severity (BCTSQ and CTS-6).
CONCLUSIONS: Ultrasound identifies the more symptomatic side in bilateral patients, which correlates with increasing severity (NCS and BCTSQ). Obesity increases median nerve CSA and prolongs nerve conduction studies without influencing CTS severity. This information can be used when considering which diagnostic test to order for CTS.
<P>PROBLEM TO BE SOLVED: To provide a method for using a sugar acid to inhibit, retard growth and/or viability of plant pathogens, e.g., prokaryotes, eukaryotes and the like, infecting to a plant or a part of the plant or ectoparasitic by other means, or to control them by other means.  <P>SOLUTION: The method is to prevent or treat infection caused by a range of fungal pathogens in animals, plants or stored plant products and includes a process for administering an effective amount of the sugar acid, above all, mannoic acid, gluconic acid or galacturonic acid. The sugar acid can be delivered by a biocontroller that can produce the sugar acid. The biocontroller is, e.g., Pseudomonas strain AN5. The strain is characterized by the capacity to convert an aldose to a sugar acid. Nucleotide sequences from a group of enzymes in the Pseudomonas PQQ enzyme pathway which may be used to transform microorganisms and plants so that they produce the sugar acids at levels sufficient to control the growth or viability of the pathogens are also disclosed.  <P>COPYRIGHT: (C)2008,JPO&INPIT
FIELD: medicine, phytotherapy. SUBSTANCE: invention relates to agents with sedative effect. The proposed agent comprises extract of a mixture of the following medicinal plants: hawthorn, hop, common balm, motherwort, coneflower and valerian taken in the ratio = 2:1:2:1:1:1, respectively. Extract is prepared by extraction with 40% ethyl alcohol taken in the ratio raw : extractant = 1:1. Agent comprises also glycine, sorbitol and water taken in the definite ratio of components. Agent can be considered to be a nootropic preparation, it has no toxicity and results to decrease of undesirable adverse effects. EFFECT: improved medicinal properties of agent. 3 cl, 7 tbl, 4 ex
The purpose of the invention is to provide a material for weight reduction diet food and the processed food using the same, that is a natural food product obtained from the materials eaten in everyday life, and very safe to the human body. There is provided a material for processed food for weight reduction diets, wherein active ingredients including histidine were extracted from Bonito essence. In addition, the present invention provides the material for processed food for weight reduction diets, wherein 12,000 mg-20,000 mg weight % of histidine is included. Furthermore, the processed food for weight reduction diets using the above-mentioned material for processed food for weight reduction diets is offered. As examples of such processed food, besides supplements in tablets and capsules soup stock powder, Furikake, and feeds for animals. etc, can be considered,
T1D is commonly treated with the administration of insulin, either by multiple insulin injections or by a continuous supply of insulin through a wearable pump. Insulin therapy allows long-term survival in individuals with T1D; however, it does not guarantee constant normal blood sugar control. Because of this, long-term type 1 diabetic survivors often develop vascular complications, such as diabetic retinopathy, an eye disease that can cause poor vision and blindness, and diabetic nephropathy, a kidney disease that can lead to kidney failure and thus kidney transplant. Some individuals with T1D develop hypoglycemia unawareness, a life-threatening condition that is not easily treatable with medication and is characterized by reduced or absent warning signals for hypoglycemia. For such individuals, pancreas or pancreatic islet transplantation are possible treatment options. Rejection of these islets by the recipient's immune system, however, can make the treatment ineffective. An immune response known as instant blood-mediated inflammatory reaction (IBMIR) results in the disruption of islet integrity and islet loss within an hour of transplantation. LMW-SD inhibits IBMIR by preventing the cascade that triggers it, when combined with pancreatic islets. The purpose of this study is to determine the safety and efficacy of LMW-SD improving the outcome of islet transplantation by preventing IBMIR.

Once a preparation of islets becomes available, participants will be randomly assigned to either the low molecular weight sulfated dextran (LMW-SD) Arm or to the Control Group/Standard of Care Arm. Participants in the LMW-SD Arm will receive LMW-SD before, with and for 5 hours after islet transplantation. Participants in the Control Group will receive heparin with the islet transplantation. All participants will also receive the oral medications, mycophenolate mofetil or sirolimus and tacrolimus or cyclosporine throughout the study. In addition, they will receive either intravenous daclizumab on the day of islet transplantation and at Week 2, 4, 6, and 8 or intravenous basiliximab on the day of islet transplantation and on Day 4. The islet transplantation will occur at the hospital and will be given via the portal vein. All participants will be eligible to receive second and third islet transplantation(s) if previous transplants fail. After each islet transplantation, study visits will occur on Days 1, 3, 7, 14, 21, 28, 75, and Months 6 and 12. At these visits, physical exams and blood collection will occur. At some visits urine collection will also occur.
Hypoxia exerts a profound influence on the tumor microenvironment and immune response, shaping treatment outcomes and prognosis. Utilizing consistency clustering, we discerned two hypoxia subtypes in OPSCC bulk sequencing data from GEO. Key modules within OPSCC were identified through weighted gene correlation network analysis (WGCNA). Core modules underwent CIBERSORT immune infiltration analysis and GSEA functional enrichment. Univariate Cox and LASSO analyses were employed to construct prognostic models for seven hypoxia-related genes. Further investigation into clinical characteristics, the immune microenvironment, and TIDE algorithm prediction for immunotherapy response was conducted in high- and low-risk groups. scRNA-seq data were visually represented through TSNE clustering, employing the scissors algorithm to map hypoxia phenotypes. Interactions among cellular subpopulations were explored using the Cellchat package, with additional assessments of metabolic and transcriptional activities. Integration with clinical data unveiled a prevalence of HPV-positive patients in the low hypoxia and low-risk groups. Immunohistochemical validation demonstrated low TDO2 expression in HPV-positive (P16-positive) patients. Our prediction suggested that HPV16 E7 promotes HIF-1α inhibition, leading to reduced glycolytic activity, ultimately contributing to better prognosis and treatment sensitivity. The scissors algorithm effectively segregated epithelial cells and fibroblasts into distinct clusters based on hypoxia characteristics. Cellular communication analysis illuminated significant crosstalk among hypoxia-associated epithelial, fibroblast, and endothelial cells, potentially fostering tumor proliferation and metastasis.
PURPOSE: A medical institution server and a method for integrating business in medical institution are provided to electronically record and manage all works of medical institution, thereby managing patients more efficiently. CONSTITUTION: A reception booth(201) generates medical chart file about the patient through client information a patient. A medical record processor(203) stores examination information and recipe information to the medical chart file. A reception processor(211) computes the amount of money claimed to a patient through the examination information and the recipe information. The reception processor performs the reception process about the computed cost. A communication unit(217) extracts a medicinal decoction data from the medial chard file.
PROBLEM TO BE SOLVED: To provide dental material having a high operating efficiency and excellent mechanical strength and a dental prosthesis having excellent handleability, excellent mechanical strength and fatigue durability. SOLUTION: This dental material is composed of fibers (B) impregnated with a polymerizable monomer composition (A) comprising 100 pts.wt. of an acrylate or a methacrylate monomer composition (a) containing at least one or more kinds of polyfunctional urethane (meth)acrylates, 0.01-5 pts.wt. of a polymerization initiator (b) and 10-100 pts.wt. of an inorganic powder (c). In the dental material, the polymerizable monomer composition (A) has 17-37 mm consistency at 25 deg.C. The dental prosthesis is prepared by using the dental material.
Patients in this group will undergo sham surgery at one location on the affected limb, and the procedure will be performed under local anesthesia. During the operation, patients will be blinded using a noise-canceling headphone and blindfolds. The locations for LVA surgery will be determined prior to the surgery using ICG lymphography. However, the incision for the sham procedure will be made 2 centimeters medial or lateral to the predetermined site. This is done in order to avoid damage to the lymph vessels as to allow for future LVA surgery. After the incision, no LVA is made. Rather than performing the actual operation, the plastic surgeon will simulate the procedure by applying pressure in the surgical area. To mimic the approximate duration of a regular LVA procedure, the sham operation will take approximately 60 to 90 minutes.
The invention discloses vitality-nourishing tonic placenta hominis wine, which is prepared by soaking 26 Chinese medical materials, such as penis cervi, cornua cervi pantotrichum, ginseng, tortoise plastron glue, placenta hominis and cynomorium songaricum with 40-degree sticky rice distilled spirit. The vitality-nourishing tonic placenta hominis wine inherits the theory of 'the best treatment for disease is precaution' in traditional Chinese medicine of 'the Internal Canon of Medicine' in China. The vitality-nourishing tonic placenta hominis wine is scientific, rigorous and reasonable in formula synthesis, adopts complex decoction and focuses on 'congenital' and 'postnatal' construction; the vitality-nourishing tonic placenta hominis wine has remarkable pharmacological effect and has no toxic or side effect. By means of summary of practical experience of several decades, the pharmacological effect and advantages of constituent parts of the vitality-nourishing tonic placenta hominis wine are sufficiently played, so that the vitality-nourishing tonic placenta hominis wine has remarkable effect and allows fast effect, and a patient can feel breakout of efficacy and is full of vigorousness and greatly boosted in Yang qi 3h after drinking the wine. The vitality-nourishing tonic placenta hominis wine is especially applicable to patients suffering from yang insufficiency of liver and kidney as well as spleen and kidney, and sub-health patients for drinking. The vitality-nourishing tonic placenta hominis wine is also suitable for adult male and female patients suffering from yang insufficiency of liver, spleen and kidney, such as fatigue, weakness, soreness and weakness of waist and knees, impotence, premature ejaculation and sexual dysfunction.
Liver fibrosis is a chronic liver disease characterized by a progressive wound healing response caused by chronic liver injury. Currently, there are no approved clinical treatments for liver fibrosis. Sevelamer is used clinically to treat hyperphosphatemia and has shown potential therapeutic effects on liver diseases. However, there have been few studies evaluating the therapeutic effects of sevelamer on liver fibrosis, and the specific mechanisms are still unclear. In this study, we investigated the antifibrotic effects of sevelamer-induced low inorganic phosphate (Pi) stress in vitro and in vivo and analyzed the detailed mechanisms. We found that low Pi stress could inhibit the proliferation of activated hepatic stellate cells (HSCs) by promoting apoptosis, effectively suppressing the migration and epithelial-mesenchymal transition (EMT) of hepatic stellate cells. Additionally, low Pi stress significantly increased the antioxidant stress response. It is worth noting that low Pi stress indirectly inhibited the activation and migration of HSCs by suppressing transforming growth factor β (TGF-β) expression in macrophages. In a rat model of liver fibrosis, oral administration of sevelamer significantly decreased blood phosphorus levels, improved liver function, reduced liver inflammation, and increased the antioxidant stress response in the liver. Our study revealed that the key mechanism by which sevelamer inhibited liver fibrosis involved binding to gastrointestinal phosphate, resulting in a decrease in blood phosphorus levels, the downregulation of TGF-β expression in macrophages, and the inhibition of HSC migration and fibrosis-related protein expression. Therefore, our results suggest that sevelamer-induced low Pi stress can attenuate hepatic stellate cell activation and inhibit the progression of liver fibrosis, making it a potential option for the treatment of liver fibrosis and other refractory chronic liver diseases.
The present invention relates to a system and method for vestibular and/or balance rehabilitation by monitoring and measuring the head motion data of a user having vestibular impairment. The system as per the present invention comprises a user device, a head tracking device, and a remote server device. The user device is configured to receive therapeutical configuration data prescribed by a therapist using the remote server device. A visual and auditory and/or haptic stimuli is generated in the user interface according to the received therapeutic configuration data during a training session or initial assessment session. The auditory stimuli comprises a metronome beat such that the frequency of the metronome beat is configured to be adjustable based on the therapeutic configuration data.Head motion data from the head tracking device during the training session is received along with user inputted data pertaining to one or more symptoms of the user. A real time sensory and corrective feedback in the user interface according to the received head motion data is provided during the training session. The remote server device is configured to receive and process the head motion and positional data, the user inputted symptoms data and communicate a set of updated therapeutic configuration data to the user device based on the processed data for use in a next training session.
Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding. Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.

Clopidogrel, an inactive thienopyridine prodrug, is metabolized in the liver by CYP3A4 to an active metabolite. A potential interaction between clopidogrel and amiodarone resulting in ineffective inhibition of platelet aggregation has been reported.

Some drugs/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction). This may lead to low amiodarone serum levels and potential decrease in efficacy. Reported examples of this interaction include the following:
FIELD: inhalers. SUBSTANCE: inhaler of dry powder-like medicament has impeller positioned eccentrically in mixing chamber. Impeller is rotated by motor at high speed. Plunger feeds dose of medicinal powder into chamber so that all particles of powder are available for mixing, decomposing and grinding. Hole receives first flow of air and directs it to mouthpiece for user's inhalation. At least one hole is provided in wall designed to deflect part of main air flow to spraying chamber for mixing with particles and forming thin low- density dry aerosol of powder-like medicament for user's inhalation. Device ensures medicament feed irrespective of patient's breathing intensity. EFFECT: enhanced efficiency. 11 cl, 37 dwg
Participants will be randomized to receive BFKB8488A. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.
PURPOSE:To prepare the titled composition which can be sprayed as fine mist without air-pollution, by compounding a spray mixture composed of an alcoholic medicinal solution for application to the human body, e.g. a hair liquid, etc. and 1,1,2-trichlorotrifluoroethane, with CO2 as propellant. CONSTITUTION:An alcoholic medicinal solution for application to the human body, e.g. a hair liquid composed of an alcoholic solution of polyvinyl pyrrolidone resin, etc., an insect repellant composed of an alcoholic solution of N,N-diethyl-m-toluamide, an anhidrotic deodorant composed of an alcoholic solution of aluminum chlorohydroxide, etc., is mixed with 1,1,2-trichlorotrifluoroethane to obtain a spray mixture, which is compounded with CO2 as a propellant to obtain the objective composition. EFFECT:Safe to the human body.
Heart failure with preserved ejection fraction (HFpEF) is commonly found in persons living with HIV (PLWH) even when antiretroviral therapy suppresses HIV viremia. However, studying this condition has been challenging because an appropriate animal model is not available. In this article, we studied calcium transient in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in culture to simulate the cardiomyocyte relaxation defect noted in PLWH and HFpEF and assess whether various drugs have an effect. We show that treatment of hiPSC-CMs with inflammatory cytokines (such as interferon-γ or TNF-α) impairs their Ca2+ uptake into sarcoplasmic reticulum and that SGLT2 inhibitors, clinically proven as effective for HFpEF, reverse this effect. Additionally, treatment with mitochondrial antioxidants (like mito-Tempo) and certain antiretrovirals resulted in the reversal of the effects of these cytokines on calcium transient. Finally, incubation of hiPSC-CMs with serum from HIV patients with and without diastolic dysfunction did not alter their Ca2+-decay time, indicating that the exposure to the serum of these patients is not sufficient to induce the decrease in Ca2+ uptake in vitro. Together, our results indicate that hiPSC-CMs can be used as a model to study molecular mechanisms of inflammation-mediated abnormal cardiomyocyte relaxation and screen for potential new interventions.
Patients receive ondansetron hydrochloride IV twice daily and saline IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive diphenhydramine hydrochloride, lorazepam, and dexamethasone by continuous infusion pump.